# Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

> **NCT03588299** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bayer** · enrollment: 11 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** BAY2599023 (DTX201)

## Key facts

- **NCT ID:** NCT03588299
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-07
- **Primary completion:** 2026-11-03
- **Final completion:** 2026-11-03
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03588299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03588299, "Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT03588299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*